Addressing Concerns Regarding the Use of Gadolinium in a Standardized MRI Protocol for the Diagnosis and Follow-Up of Multiple Sclerosis

References

1. 1.↵
   2. Traboulsee A,
   3. Simon JH,
   4. Stone L, et al

   . Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis. AJNR Am J Neuroradiol 2016;37:394–401 doi:10.3174/ajnr.A4539 pmid:26564433

   Abstract/FREE Full Text
2. 2.↵
   U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA evaluating the risk of brain deposits with repeated use of gadolinium-based contrast agents for magnetic resonance imaging (MRI). Safety Announcement. July 27, 2015. http://www.fda.gov/Drugs/DrugSafety/ucm455386.htm. Accessed June 29, 2016.
3. 3.↵
   2. Ramalho J,
   3. Semelka RC,
   4. Ramalho M, et al

   . Gadolinium-based contrast agent accumulation and toxicity: an update. AJNR Am J Neuroradiol 2016;37:1192–98 doi:10.3174/ajnr.A4615 pmid:26659341

   Abstract/FREE Full Text
4. 4.↵
   2. Lublin FD,
   3. Reingold SC,
   4. Cohen JA, et al

   . Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014;83:278–86 doi:10.1212/WNL.0000000000000560 pmid:24871874

   CrossRefPubMed